CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: Impact of pre-inflammatory stimuli and renin-angiotensin system modulators

Thrombosis Research

Volumn 121, Issue 3, 2007, Pages 387-395

  Apostolakis, Stavros ^a   Krambovitis, Elias ^b,c   Vlata, Zaharenia ^b,c   Kochiadakis, Georgios E ^a   Baritaki, Stavroula ^a   Spandidos, Demetrios A ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b INSTITUTE OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY   (Greece)

^c UNIVERSITY OF THESSALY   (Greece)

Author keywords

ACE inhibitors; Angiotensin receptor blockers; Chemokine receptors; CX3CR1; Monocytes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GAMMA INTERFERON; LISINOPRIL; LOSARTAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BONFERRONI CORRECTION; CELL ACTIVITY; CELL ISOLATION; CELL STIMULATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DONOR; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; LEUKEMIA CELL LINE; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STATISTICAL CONCEPTS; STATISTICAL SIGNIFICANCE; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; CASE-CONTROL STUDIES; CELL LINE; CORONARY ARTERY DISEASE; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERFERON-GAMMA, RECOMBINANT; JURKAT CELLS; LISINOPRIL; LOSARTAN; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, CHEMOKINE; RENIN-ANGIOTENSIN SYSTEM; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 37749054645     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.04.005     Document Type: Article

References (46)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 340 (1999) 115-126
2. Luster A.D. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 338 (1998) 436-445
3. Reape T.J., and Groot P.H. Chemokines and atherosclerosis. Atherosclerosis 147 (1999) 213-225
4. Weber C., Schober A., and Zernecke A. Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 24 (2004) 1997-2008
5. Das U.N. Is angiotensin-II an endogenous pro-inflammatory molecule?. Med Sci Monit 11 (2005) RA155-RA162
6. Ferrario C.M., and Strawn W.B. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 98 (2006) 121-128
7. Pueyo M.E., Gonzalez W., Nicoletti A., Savoie F., Arnal J.F., and Michel J.B. Angiotensin II stimulates endothelial cell adhesion molecule-I via nuclear factor-kB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 20 (2000) 645
8. Ushio-Fukai M., Alexander R.W., Akers M., Yin Q., Fujio Y., Walsh K., et al. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem 274 (1999) 22699-22704
9. He M., He X., Xie Q., Chen F., and He S. Angiotensin II induces the expression of tissue factor and its mechanism in human monocytes. Thromb Res 117 (2006) 579-590
10. 2+ mobilization and protein kinase C activation. J Biol Chem 264 (1989) 526-530
11. Dezso B., Jacobsen J., and Poulsen K. Evidence for the presence of angiotensins in normal, unstimulated alveolar macrophages and monocytes. J Hypertens 7 (1989) 5-11
12. Yusuf S., Pepine C.J., Garces C., Pouleur H., Salem D., Kostis J., et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 340 (1992) 1173-1178
13. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343 (1994) 1115-1122
14. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
15. Powell J.S., Clozel J.P., Muller R.K., Kuhn H., Hefti F., Hosang M., et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245 (1989) 186-188
16. van Leeuwen R.T., Kol A., Andreotti F., Kluft C., Maseri A., and Sperti G. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 90 (1994) 362-368
17. Schindler R., Dinarello C.A., and Koch K.M. Angiotensin-converting enzyme inhibitors suppress synthesis of tumor necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine 7 (1995) 526-533
18. Pfeffer M.A., McMurray J.J., Velazquez E.J., Rouleau J.L., Kober L., Maggioni A.P., et al. Valsartan in acute myocardial infarction trial investigators: valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
19. Dickstein K., and Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group: effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAL randomized trial. Lancet 360 (2002) 752-760
20. Dandona P., Kumar V., Aljada A., Ghanim H., Syed T., Hofmayer D., et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kB, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 88 (2003) 4496-4501
21. Bazan J.F., Bacon K.B., Hardiman G., Wang W., Soo K., Rossi D., et al. A new class of membrane bound chemokine with a CX3C motif. Nature 385 (1997) 640-644
22. Imai T., Hieshima K., Haskell C., Baba M., Nagira M., Nishimura M., et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91 (1997) 521-530
23. Wong B.W., Wong D., and McManus B.M. Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol 11 (2002) 332-338
24. Lucas A.D., Bursill C., Guzik T.J., Sadowski J., Channon K.M., and Greaves D.R. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation 108 (2003) 2498-2504
25. Combadiere C., Potteaux S., Gao J.L., Esposito B., Casanova S., Lee E.J., et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107 (2003) 1009-1016
26. Schafer A., Schulz C., Eigenthaler M., Fraccarollo D., Kobsar A., Gawaz M., et al. Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion. Blood 103 (2004) 407-412
27. Zafiropoulos A., Andersson E., Krambovitis E., and Borrebaeck C.A. Induction of antigen-specific isotype switching by in vitro immunization of human naive B lymphocytes. J Immunol Methods 200 (1997) 181-190
28. Adams D.J., Head G.A., Markus M.A., Lovicu F.J., van der Weyden L., Kontgen F., et al. Renin enhancer is critical for control of renin gene expression and cardiovascular function. J Biol Chem 281 (2006) 31753-31761
29. Phillips M.I., and Kagiyama S. Angiotensin II as a pro-inflammatory mediator. Curr Opin Investig Drugs 3 (2002) 569-577
30. Kitazono T., Padgett R.C., Armstrong M.L., Tompkins P.K., and Heistad D.D. Evidence that angiotensin II is present in human monocytes. Circulation 15 (1995) 1129-1134
31. Blum A., and Miller H. Role of cytokines in heart failure. Am Heart J 135 (1998) 181-186
32. Sasayama S., Matsumori A., and Kihara Y. New insights into the pathophysiological role for cytokines in heart failure. Cardiovasc Res 42 (1999) 557-564
33. Levine B., Kalman J., Mayer L., Fillit H.M., and Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 (1990) 236-241
34. Bristow M.R. Tumor necrosis factor- and cardiomyopathy. Circulation 97 (1998) 1340-1341
35. Porber J.S., and Corton R.S. Cytokines and endothelial cell biology. Physiol Rev 70 (1990) 427-451
36. Farrar M.A., and Schreiber R.D. The molecular cell biology of interferon-γ and its receptor. Annu Rev Immunol 11 (1993) 571-611
37. Gupta S., Pablo A.M., Jiang X., Wang N., Tall A.R., and Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 99 (1997) 2752-2761
38. Boehm U., Klamp T., Groot M., and Howard J.C. Cellular responses to interferon-γ. Annu Rev Immunol 15 (1997) 749-795
39. Apostolakis S., Papadakis G.E., Krambovitis E., and Spandidos D.A. Chemokines in vascular pathology. Int J Mol Med 17 (2006) 691-701
40. Apostolakis S., Baritaki S., Kochiadakis G.E., Igoumenidis N.E., Panutsopulos D., and Spandidos D.A. Effects of polymorphisms in chemokine ligands and receptors on susceptibility to coronary artery disease. Thromb Res 119 (2007) 63-71
41. Tsuchiya S., Yamabe M., Yamaguchi Y., Kobayashi Y., Konno T., and Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 26 (1980) 171-176
42. Mak I.T., Freedman A.M., Dickens B.F., and Weglicki W.B. Protective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochem Pharmacol 40 (1990) 2169-2175
43. Liu X., Engelman R.M., Ronson J.A., Cordis G.A., and Das D.K. Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors. Cardiovasc Drugs Ther 6 (1992) 437-443
44. Chopra M., Beswick H., Clapperton M., Dargi H.J., Smith H.J., and Mc-Murray J. Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl-containing ACE inhibitors. J Cardiovasc Pharmacol 19 (1992) 330-340
45. Constantinescu C.S., Goodman D.B.P., and Ventura E.S. Captopril and lisinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells. Immunol Lett 62 (1998) 25-31
46. Leehey D.J., Isreb M.A., Marcic S., Singh A.K., and Singh R. Effect of high glucose on superoxide in human mesangial cells: role of angiotensin II. Nephron Exp Nephrol 100 (2005) e46-e53